“But I remain optimistic about the future of prescription medicines to treat Covid-19 in eligible patients, and the role they will continue to play in the broader care landscape.” Pharmaceutical Executive: High-risk patients are still getting seriously ill and being hospitalized from Covid-19. For those eligible, prescription medicines like Paxlovid (nirmatrelvir 150mg tablets; ritonavir 100mg tablets) remain an important consideration for patient care. Dr. Sidhu: Multiple real-world analyses, including those conducted during the Omicron era, have illustrated the safety and effectiveness of Paxlovid in preventing severe outcomes from Covid-19 infection, among eligible patients. This growing body of evidence highlights the important role that Paxlovid plays in supporting eligible patients, providers, and health care systems around the world.